OnabotulinumtoxinA Improves Health-Related Quality of Life in Patients With Urinary Incontinence Due to Idiopathic Overactive Bladder: A 36-Week, Double-Blind, Placebo-Controlled, Randomized, Dose-Ranging Trial Full Text
European Urology, 06/21/2012
Clinical Article
Fowler CJ et al. – A single onabotulinumtoxinA treatment with doses ≥100 U resulted in statistically significant and clinically meaningful improvement in health–related quality–of–life by week 2 compared with placebo, and this improvement was sustained for ≤36 wk in patients with idiopathic overactive bladder and urgency urinary incontinence who were inadequately managed by oral antimuscarinics.



